Canopy Growth Corporation is a Canadian cannabis and consumer packaged goods company headquartered in Smiths Falls, Ontario. The company produces and distributes medical and adult-use cannabis across Canada and internationally, and it is Canada's leading medical cannabis provider by revenue through its Canada House Clinics network and Abba Medix platform.
Its brand portfolio includes Tweed, 7ACRES, DOJA, Deep Space, DeeLish, MTL Cannabis, and Claybourne, alongside the premium vaporizer maker Storz & Bickel. Canopy Growth also holds an unconsolidated, non-controlling interest in Canopy USA, a structure that provides exposure to the U.S. THC market. Investors follow the stock as a barometer for the Canadian cannabis industry and for the sector's broader path toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, CGC declined approximately 34.7%, falling from a closing price near $0.67 on October 21, 2026 to about $0.44 by November 20. The decline accelerated in the sessions following the company's November 6 earnings release and continued through mid-November amid broad weakness across cannabis names.
The quarterly picture is similarly downbeat. About three months ago, CGC traded near $1.05 in late August. The stock has since shed roughly 58%, reflecting a steady, multi-month downtrend punctuated by sharper sell-offs after earnings and on days of elevated volume. The persistent decline underscores how investor focus has remained on profitability, dilution, and balance-sheet risks rather than on top-line growth.
Canopy Growth's fiscal second-quarter report, released on November 6, 2026, was the dominant catalyst. Consolidated net revenue rose 22% year over year to about C$81.4 million, and international markets cannabis revenue climbed 141% to roughly C$12.3 million, driven by Germany and Poland. However, the company posted a wider net loss than analysts expected, largely because of a sizable non-cash fair value charge on assets tied to Canopy USA. Earnings per share missed consensus, and revenue came in slightly below estimates.
The reaction underscored investor sensitivity to items beyond revenue growth. The large fair value write-down re-focused attention on Canopy USA, where debt linked to the Acreage and Wana interests remains in default under a forbearance arrangement with a deadline early next year. At the same time, a lower reimbursement rate from Veterans Affairs Canada continued to pressure Canadian medical margins, and the Storz & Bickel vaporizer business posted weaker sales.
Sentiment was also shaped by capital-structure news. Investors approved a proposed share consolidation, which followed a period in which heavy equity issuance had diluted shareholders. Analyst actions were mixed: Alliance Global lowered its price target to C$1.25 from C$1.60 while keeping a Neutral rating, whereas Roth Capital Partners maintained a Buy rating and a C$5.00 target. Broad sector rotation and ongoing weakness across cannabis equities amplified the downward pressure. From what I see, I also checked this using Tickeron’s AI Pattern Search Engine to confirm pattern signals around the earnings date.
The stock's roughly 58% decline over the trailing three months reflects a larger narrative than any single catalyst. Canopy Growth has been executing a multi-year restructuring aimed at cutting costs, improving cultivation efficiency, and reaching positive adjusted EBITDA. While revenue has grown and losses have narrowed, investors have continued to weigh persistent net losses, gross-margin pressure, and the overhang of share dilution against the company's operational progress.
The acquisition of MTL Cannabis strengthened Canopy's Canadian medical position and added premium flower capabilities, and EU GMP certifications across its supply chain support European expansion. Yet recurring non-cash charges, the unresolved status of Canopy USA's debt, and reimbursement headwinds in Canada have kept sentiment cautious. The result has been a grind lower in the share price even as management has reiterated its target of positive adjusted EBITDA during fiscal 2027.
Several factors will likely shape CGC's path in the coming quarters. First, investors will monitor whether management delivers on its goal of positive adjusted EBITDA during fiscal 2027, with improvements expected to be more pronounced in the second half of the fiscal year. Second, the Canopy USA forbearance deadline early next year is a key structural risk, as the status of debt tied to Acreage and Wana could trigger further fair value adjustments.
Third, Canadian medical margins will depend on how effectively the company offsets the reduced Veterans Affairs Canada reimbursement rate through pricing and product-mix changes. Fourth, international growth in Germany, Poland, and newly entered markets such as the United Kingdom will be watched for sustained momentum. Finally, the outcome of the approved share consolidation and any further use of the at-the-market equity program will influence share count and sentiment. These are factual risk factors to monitor rather than a basis for investment decisions. I’m watching this closely as the forbearance deadline approaches.
I often turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like CGC amid volatile periods. The platform aggregates data-driven signals across thousands of tickers, helping me cross-check momentum, trend, and pattern insights without replacing my own fundamental review. It has become a useful supplement when scanning for comparable setups in the cannabis space or broader market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CGC saw its Momentum Indicator move below the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 74 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 39 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CGC entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (6.379). P/E Ratio (-0.972) is within average values for comparable stocks, (0.548). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of medical marijuana
Industry PharmaceuticalsGeneric